Obermatt
See Similar Stocks →

EyePoint

NMQ:EYPT · US30233G2093
PharmaceuticalsSmall

360

34
Profit price73
Owner Earnings Yield1
Dividend Yield1
Price/Sales1
Price/Book100
Return on Capital1
Cash Return on Capital4
Return on Equity4
Profit margins1
Accruals95
Owner Earnings Margin4
Sales growth1
Profit growth11
Reinvestment44
Price momentum67
Debt load61
Refinancing42
Debt Payback1
Liquidity1
Analyst ratings67
Opinion Changes18
Price Target Upside92
Market mood47
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

EyePoint doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2008
Employees213
Websiteeyepoint.bio
ISINUS30233G2093
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OphthalmologyInflammationDiabetesBiotechnologyDeveloper PlatformMedical

Description

EyePoint, Inc., a clinical-stage biopharmaceutical company, develops and commercializes innovative therapeutics to help improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Duraser…

Analysis

Weak and unloved

EyePoint, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
9
2023202420252026

All-time high

64

Jan 2024

All-time low

4

Mar 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
7
7
28
Price/Earnings
58
26
26
26
Price/Book
100
64
9
46
Dividend Yield
1
1
1
1
Value (overall)
50
29
6
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare EyePoint with its peers
CalciMedica
NAQ:CALC
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Pliant Therapeutics
NSQ:PLRX
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
AnaptysBio
NSQ:ANAB
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Fulcrum Therapeutics
NMQ:FULC
24
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →